RxDoctor Payments Data

Kenneth Sibila, MD

Family Medicine · Towson, MDNPI 1386615185

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 86 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$292
  • Amgen$206
  • E.r. Squibb & Sons, L.L.C.$183
  • Novartis$125
  • Amarin Pharma, Inc.$122
  • Lilly USA, LLC$88
  • plus $392 from 12 others

What the payments were for

  • Food & beverage$1,401100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,407 in reported general payments places this provider in the 70th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$135,464
Medicare patients
282
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide47$61,782
OzempicSemaglutide26$39,297
JanuviaSitagliptin Phosphate18$19,818
EliquisApixaban16$18,982
MyrbetriqMirabegron14$17,646
CreonLipase/Protease/Amylase12$16,068
XareltoRivaroxaban11$13,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$13,631
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$8,451
Repatha SureclickEvolocumab13$7,167
Rosuvastatin Calcium298$5,988
SynthroidLevothyroxine Sodium51$3,382
Atorvastatin Calcium174$2,463
Levothyroxine Sodium212$2,395
Pravastatin Sodium92$2,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$88$61,78247 claims
Novo NordiskOzempic$18$39,29726 claims
GSKTrelegy Ellipta, Anoro Ellipta$62$22,08239 claims
MerckJanuvia$52$19,81818 claims
AbbVieCreon, Synthroid$59$19,45063 claims
PfizerEliquis$25$18,98216 claims
Astellas Pharma US IncMyrbetriq$16$17,64614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →